Skip to main content
. Author manuscript; available in PMC: 2018 Dec 17.
Published in final edited form as: Mol Cancer Res. 2017 Feb 16;15(6):660–669. doi: 10.1158/1541-7786.MCR-17-0028

Figure 1.

Figure 1.

G1T28 inhibits cell-cycle progression in models of prostate cancer. A, LNCaP, VCaP, or 22Rv1 cells were plated in media containing 10% FBS and treated with increasing concentrations of enzalutamide, docetaxel, palbociclib, or G1T28 (10−10-10−4.3 mol/L) and measured for cell viability by Hoechst staining after 5 to 7 days of treatment. B and C, LNCaP, VCaP, or 22Rv1 cells were plated in media containing 10% FBS with increasing concentrations of G1T28 (10−9.5-10−6 mol/L) for 24 hours and then stained with PI for cell-cycle analysis (B) or fixed, permeabilized, and stained for phospho (Ser 807/811) and total Rb using a LI-COR Odyssey Clx imager (C). Dose–response curves were generated from densitometry of the phospho and total retinoblastoma expression using LI-COR Image Studio software. Data are representative of at least three independent experiments.